{"id":1019326,"date":"2026-11-10T07:35:37","date_gmt":"2026-11-10T12:35:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-third-quarter-2026-financial-results\/"},"modified":"2026-11-10T07:35:37","modified_gmt":"2026-11-10T12:35:37","slug":"exagen-inc-reports-third-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-third-quarter-2026-financial-results\/","title":{"rendered":"Exagen Inc. Reports Third Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n Third Quarter Revenue Grew 7% to $18.4 Million\u00a0<\/em>\n <\/p>\n

\n Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30%<\/p>\n

<\/em>\n <\/p>\n

CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and recent corporate updates.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\n Three Months Ended September 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Nine Months Ended September 30,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Unaudited. In thousands, except ASP data.<\/em>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Revenue<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a018,417<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a017,244<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a055,664<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a049,944<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a058.8<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a058.4<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a059.7<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a059.3<\/td>\n%<\/td>\n<\/tr>\n
Operating expenses<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a015,244<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a013,175<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a042,802<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a038,688<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating loss<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(4,408<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(3,100<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(9,544<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(9,095<\/td>\n)<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(6,336<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(7,087<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(13,499<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(15,278<\/td>\n)<\/td>\n<\/tr>\n
Adjusted EBITDA<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(1,932<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(1,895<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(4,206<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0(6,124<\/td>\n)<\/td>\n<\/tr>\n
Trailing twelve-month average selling price (ASP)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0451<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0441<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0451<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a0441<\/td>\n\u00a0<\/td>\n<\/tr>\n
Cash and cash equivalents (as of September 30)<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a028,092<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a035,652<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a028,092<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n\u00a035,652<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Third Quarter 2026 and Recent Corporate Highlights:<\/strong>\n <\/p>\n